- Iovance Biotherapeutics (NASDAQ:IOVA) announces that it ended Q2 with $276.1M in cash. Net loss for the quarter was $30.7M.
- European sites activated in five countries for two clinical trials evaluating tumor-infiltrating lymphocytes. Enrollment and dosing underway in Phase 2 melanoma study.
- Update on melanoma program (four studies) will be provided later this year.
- Shares are down 1% after hours.
Iovance Bio ended Q2 with $276.1M in cash; shares down 1% after hours
Recommended For You
About IOVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
IOVA | - | - |
Iovance Biotherapeutics, Inc. |